These findings build on a recent multicenter retrospective study of over 4 million hospitalized patients published in the American Journal of Cardiology that also demonstrated that echocardiography ...
BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...
N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Lantheus Medical Imaging announced that the Food and Drug Administration (FDA) has approved a label update for Definity (perflutren lipid microsphere) injectable suspension with the removal of a ...
October 15, 2007 (Rockville, MD)-As expected, the US FDA has requested that a boxed warning be added to the labeling of two contrast agents used in echocardiography: perflutren liquid microspheres ...
Please provide your email address to receive an email when new articles are posted on . Lantheus Medical Imaging Inc. announced that the FDA has approved a label update that removes the ...
Lantheus (NASDAQ:LNTH) reported what management described as a strong start to 2026, citing solid performance from its three core commercial products—PYLARIFY, Neuraceq® and DEFINITY—and progress on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results